These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36372608)

  • 1. Evidence on the effectiveness of policies promoting price transparency - A systematic review.
    Joosse IR; Tordrup D; Glanville J; Kotas E; Mantel-Teeuwisse AK; van den Ham HA
    Health Policy; 2023 Aug; 134():104681. PubMed ID: 36372608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain.
    Joosse IR; Tordrup D; Glanville J; Mantel-Teeuwisse AK; van den Ham HA
    Health Policy; 2023 Dec; 138():104919. PubMed ID: 37788559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.
    Lee IH; Bloor K; Hewitt C; Maynard A
    J Health Serv Res Policy; 2015 Jan; 20(1):52-9. PubMed ID: 25092883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
    Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
    Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug price transparency initiative: A scoping review.
    Ahmad NS; Makmor-Bakry M; Hatah E
    Res Social Adm Pharm; 2020 Oct; 16(10):1359-1369. PubMed ID: 31987771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of studies reporting actual prices for medicines.
    Mardetko N; Kos M; Vogler S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.
    Franzen N; Ziegler A; Romagnoli G; Retèl VP; Offerman TJS; van Harten WH
    Cancer Res Commun; 2022 Jan; 2(1):49-57. PubMed ID: 36860697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic reviews of ten pharmaceutical pricing policies - a research protocol.
    Tordrup D; van den Ham HA; Glanville J; Mantel-Teeuwisse AK
    J Pharm Policy Pract; 2020; 13():22. PubMed ID: 32695425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon.
    Abdel Rida N; Mohamed Ibrahim MI; Babar ZUD
    BMC Health Serv Res; 2019 Dec; 19(1):973. PubMed ID: 31852546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
    Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
    Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs).
    Babar ZU
    Res Social Adm Pharm; 2024 Sep; 20(9):934-939. PubMed ID: 38908991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea.
    Kim W; Koo H; Lee HJ; Han E
    Int J Health Policy Manag; 2022 Oct; 11(10):2198-2207. PubMed ID: 34814666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.